{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["spartalizumab","canakinumab"]],"indication":"localized clear cell renal cell carcinoma","name":"SPARC-1","nct_id":"NCT04028245","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sparc-1-nct04028245. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SPARC-1","arms":[{"description":"Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.","label":"Spartalizumab and Canakinumab","type":"EXPERIMENTAL"}],"collaborators":["Novartis"],"completion_date":{"date":"2026-03-05","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":17,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Spartalizumab","otherNames":["PDR-001"],"type":"DRUG"},{"name":"Canakinumab","otherNames":["ACZ885"],"type":"DRUG"}],"last_update":"2026-04-15","lead_sponsor":"Columbia University","official_title":"A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)","overall_status":"COMPLETED","phases":["EARLY_PHASE1"],"primary_completion_date":{"date":"2025-03-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of subjects who proceed to radical nephrectomy","timeFrame":"6 Weeks"}],"references":[],"start_date":{"date":"2019-08-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT04028245"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sparc-1-nct04028245"}